Medical Marijuana Explosion Continues as Company Agrees to Purchase 83,000 S/F Complex in AZ

Medical Marijuana Explosion Continues as Company Agrees to Purchase 83,000 S/F
                                Complex in AZ

PR Newswire

CORAL SPRINGS, Florida, February 19, 2014

CORAL SPRINGS, Florida, February 19, 2014 /PRNewswire/ --

Alternative care industry sees growth as medical marijuana companies continue
expansion: Zoned Properties, Inc. (OTC: ZDPY), Growlife, Inc. (OTCBB: PHOT),
Advanced Cannabis Solutions, Inc. (OTCBB: CANN) Chelsea Therapeutics
International Ltd. (NASDAQ: CHTP) and GW Pharmaceuticals plc (NASDAQ: GWPH)

Zoned Properties, Inc. (OTC: ZDPY), a lessor of
land, facilities and equipment to the medical marijuana market has entered
into a definitive agreement and opened escrow on a multi-tenant industrial
complex in Tempe, Arizona. The company is currently in the due diligence
period and expects to close on the property within sixty (60) days. The
facility has several tenants including a state licensed Arizona medical
marijuana cultivator. The 83,000 square foot facility sits on 5.3 acres and is
being purchased for $4.6 million.

To read the full press release, please click

Newly appointed V.P. of Operations and C.S.O. Bryan McLaren stated "This
purchase represents the type of commercial transaction that Zoned Properties,
Inc. aspires to accomplish. This property is in the heart of downtown Tempe,
Arizona located in very close proximity to Phoenix Sky Harbor Airport as well
as many major highways. We believe a purchase like this gives us a great asset
base to build off as we continue to execute our strategy of acquiring uniquely
zoned properties."

Growlife, Inc. (OTCBB: PHOT) a diversified company operating in the legal
cannabis industry which develops, markets and deploys products and services of
legal cannabis is pleased to announce that shares sufficient to constitute a
quorum under the Company's Bylaws were present either in person or by proxy at
the February 7, 2014, special meeting of shareholders and, therefore, the
Company transacted business. The preliminary voting results indicate
506,035,500 shares of the common stock of the Company voted in favor of the
proposal. This represents 88.2% of the shares entitled to vote on the sole
proposed item, which was an amendment of the Company's Certificate of
Incorporation increasing the number of shares of common stock the Company is
authorized to issue from 1,000,000,000 to 3,000,000,000.

Advanced Cannabis Solutions, Inc. (OTCBB: CANN) recently signed a definitive
agreement with Full Circle Capital Corporation, a closed-end investment
company.The agreement provides that the investment fund will initially
provide $7.5 million to the Company in the form of Senior Secured Convertible
Notes, subject to certain conditions.An additional $22.5 million can be
borrowed by Company with the mutual agreement of the Company and the
investment company. At least 95% of the loan proceeds will be used to acquire
properties which the Company, consistent with its business plan, will lease to
licensed cannabis growers. The six-year loan will be secured by real estate
acquired with the loan proceeds, and will require interest-only payments at a
rate of 12% per year.

Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) announced that the U.S.
Food and Drug Administration (FDA) granted accelerated approval of
NORTHERA^[^TM^](droxidopa)for the treatment of symptomatic neurogenic
orthostatic hypotension (NOH). NORTHERA is the first and only therapy approved
by the FDA which demonstrates symptomatic benefit in patients with NOH.
NORTHERA is indicated for the treatment of orthostatic dizziness,
lightheadedness, or the "feeling that you are about to black out" in adult
patients with symptomatic NOH caused by primary autonomic failure (Parkinson's
disease, multiple system atrophy and pure autonomic failure), dopamine beta
hydroxylase deficiency and non-diabetic autonomic neuropathy.

GW Pharmaceuticals plc (NASDAQ: GWPH) a biopharmaceutical company, together
with its subsidiaries, is engaged in discovering, developing, and
commercializing cannabinoid prescription medicines. The company operates
through three segments: Sativex Commercial, Sativex Research and Development,
and Pipeline Research and Development. The company primarily offers Sativex,
an oromucosal spray for the treatment of MS symptoms, cancer pain, and
neuropathic pain. It also focuses on the Phase III clinical development
program of Sativex for use in the treatment of cancer pain. In addition, the
company's product pipeline includes an orphan childhood epilepsy program, as
well as other product candidates in Phase I and II clinical development for
the treatment of glioma, ulcerative colitis, type-2 diabetes, and
schizophrenia. It has a strategic alliance with Otsuka Pharmaceutical Co.,
Ltd.On Tuesday, GWPH closed down 1.66% on over 300 thousand shares traded.

FinancialNewsMedia.comis leading provider of third party publishing &news
dissemination services. If you would like more information regarding our news
coverage solutions, please visithttp://www.financialnewsmedia.comfor more
details. Get an edge on the market with ourPremium News Alertsthat are
FREE for a limited time at Follow us on

DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news
dissemination service provider, which disseminates electronic information
through multiple online media channels. FNMG is NOT affiliated in any manner
with any company mentioned herein. FNMG and its affiliated companies are a
news dissemination and financial marketing solutions provider and are NOT a
registered broker/dealer/analyst/adviser, holds no investment licenses and may
NOT sell, offer to sell or offer to buy any security. FNMG's market updates,
news alerts and corporate profiles are NOT a solicitation or recommendation to
buy, sell or hold securities. The material in this release is intended to be
strictly informational and is NEVER to be construed or interpreted as research
material. All readers are strongly urged to perform research and due
diligence on their own and consult a licensed financial professional before
considering any level of investing in stocks. The companies that are
discussed in this release may or may not have approved the statements made in
this release. FNMG is not liable for any investment decisions by its readers
or subscribers. Investors are cautioned that they may lose all or a portion
of their investment when investing in stocks. For current services performed
FNMG has been compensated one thousand dollars for news coverage of the
current press release issued by Zoned Properties, Inc. by the company.


This release contains "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E the
Securities Exchange Act of 1934, as amended and such forward-looking
statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. "Forward-looking statements"
describe future expectations, plans, results, or strategies and are generally
preceded by words such as "may", "future", "plan" or "planned", "will" or
"should", "expected," "anticipates", "draft", "eventually" or "projected". You
are cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause future circumstances, events, or results to
differ materially from those projected in the forward-looking statements,
including the risks that actual results may differ materially from those
projected in the forward-looking statements as a result of various factors,
and other risks identified in a company's annual report on Form 10-K or 10-KSB
and other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue reliance on
such statements. The forward-looking statements in this release are made as of
the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:
Company: FN Media Group, LLC
Contact email:
U.S. Phone: 1(954)345-0611

Press spacebar to pause and continue. Press esc to stop.